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We described a novel tumor-associated immunosuppressive mechanism based on post-translational modifications of
chemokines by reactive nitrogen species (RNS). To overcome tumor immunosuppressive hindrances, we designed and
developed a new drug, AT38, that inhibits RNS generation at the tumor site. Combinatorial approaches with AT38 boost
the effectiveness of cancer immunotherapy protocols.
The paradigm of cancer immunoediting is
an emerging cornerstone of current tumor
immunology. Tumors established various
overlapping mechanisms to escape from
immunosurveillance by sculpting host
immune responses and angiogenesis.
1,2
Tumor-induced T-cell tolerance is one
of the major hurdles (primarily exerted
by regulatory lymphoid and myeloid cells)
that favors cancer progression and spread-
ing. Successful localization of tumor-specific
cytotoxic T cells (CTLs) is widely recog-
nized as a crucial determinant of tumor
immunity. The prognostic value of tumor-
infiltrating lymphocyte (TIL) presence
within the tumor mass has been advanced
by a number of studies in the last years.
However, this pioneer concept was defi-
nitively strengthened by the finding that
high numbers of cytotoxic and memory T
cells in human colorectal cancer patient
biopsies is predictive of positive pro-
gnosis, independently from cancer stage.
3
Among the paralyzing factors circumvent-
ing T cell access to the tumor, we previ-
ously indicated the intratumoral generation
of reactive nitrogen species (RNS)
through a deregulated metabolism of
L-arginine by arginase and nitric oxide
synthase (NOS).
4
It was recently documented how nitra-
tive stress directly affects T-cell signal-
ing molecules leading to T-lymphocyte
dysfunction.
5,6 Nitrotryrosine detection
represents a trustworthy marker of the in
situ RNS release and biological activity.
In human cancer, the “nitro proteome”
extent is quite heterogeneous. While
examining the occurrence of this pheno-
menon in various human tumors, we
repeatedly observed an opposite correla-
tion between nitrotyrosine staining and
T cell positioning within primary tumor
lesions. As tuners of cell migration,
chemokine networks are frequently affec-
ted by cancer cells to promote tumor
growth and spreading. We speculated that
CCL2, an inflammatory chemokine foster-
ing both CTL and myeloid cell recruit-
ment to tumors, could be modified by
RNS assault. To detect directly the pre-
sence of the RNS-modified chemokine
in cancer specimens, we isolated a single-
domain recombinant antibody from a
llama naïve library, which specifically
interacts with the nitrosylated/nitrated
CCL2 (N-CCL2). By the use of this new
reagent, we demonstrated the presence of
N-CCL2 in human prostate and colon
carcinomas, and found that it directly
correlates with the intratumoral nitrotyro-
sine staining. In the same tumors, CTLs
were gathered at the periphery, outside
the areas positive for nytrotyrosine, sug-
gesting that N-CCL2 was not effective
in recruiting T cells. This hypothesis was
supported by in vitro experiments high-
lighting an almost completely defective
T lymphocyte migration in response to
N-CCL2 stimulation. Conversely, mye-
loid cells retained their ability to sense
N-CCL2 gradients. This antithetical
behavior, likely dependent on the lower
expression of CCL2 receptor (CCR2) in T
cells compared with myeloid cells, could
account for the intratumor preferential
accumulation of the myeloid subset,
including tumor-associated macrophages
(TAMs) and myeloid-derived suppressor
cells (MDSCs), instead of tumor-antigen
specific CTLs. As extensively reported,
tumor-recruited MDSCs contribute to
RNS generation
4 feeding the vicious circle
leading to N-CCL2 formation.
Intravital imaging studies in mouse
models have unraveled T cell leading paths
within the tumor environment.
7,8 Investi-
gating by two photon microscopy TIL
mobility within TC-1 lung epithelial
tumors, Mrass and colleagues concluded
that antigen recognition was a critical
determinant of T-cell migration within
tumors.
7 In the absence of recognized road
signs, however, antigen-experienced CTLs
failed to infiltrate tumor primary lesion,
gathering at the periphery. Indeed, RNS
appear to block T-cell entrance to the
tumor mass exploiting a post-translational
masking of chemokines. We documented
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sine and N-CCL2 in different mouse
tumor models. While considering local-
ization in these tumors, we confirmed a
preferential distribution of T cells at the
periphery of the neoplastic lesions. Even
adoptively transferred OT-1 cells, bearing
an high avidity TCR for ovalbumin
(OVA), congregated at tumor surrounding
stroma in EG-7-OVA tumors and did not
efficiently infiltrate the tumor core.
RNS generation thus prevents an effec-
tive CTL recruitment to the tumor by
raising a tumor-related chemical barrier.
Previous studies suggested that blocking
RNS production could restore T cell res-
ponsiveness and improve antitumor res-
ponses.
9,10 Reasoning on these preliminary
findings, we designed and developed a
new compound - AT38 - that efficiently
interferes with RNS generation by modu-
lating ARG and NOS enzyme expression.
A time-scheduled administration of AT38
in tumor-bearing mice caused a reduction
in nitrotyrosine formation and the sub-
sequent unmasking of TIL chemoattrac-
tant signals. Given these promising results,
we tested AT38 in combination with pas-
sive immunotherapy. Adoptive cell ther-
apy (ACT) for cancer is one of the most
promising immunotherapy approaches;
nevertheless current ACT protocols are
limited by a number of variables. In both
Figure1. RNS which are generated at a costant rate within the tumor mass stably modify CCL2. N-CCL2 is a poor chemoattractant for T cells. Conversely
MDSCs, which express high CCR2 levels, retain the ability to sense N-CCL2 gradients. In this scenario, insensitive CTLs are trapped at the periphery of the
tumor, while receptive MDSCs accumulate within the tumor mass sustaining cancer growth. AT38 blocks RNS production and overcomes tumor-
dependent immunosuppressive constrains promoting recruitment of TILs to the tumor where they can exert their killing activity.
390 OncoImmunology Volume 1 Issue 3EG-7 thymoma and MCA-203 fibrosar-
coma models, the combination of AT38
with ACT protocols allowed the adop-
tively transferred, tumor-specific CTLs to
migrate properly to the tumor core and
promote tumor rejection. AT38 might
have multiple effects, for example, it could
increase CTL recognition of tumor cells
that are rendered defective in presentation
of their tumor antigens through Class I
MHC molecule by nitrative stress
2 and
decrease the immunosuppressive activity
of MDSCs within the tumor environ-
ment.
10 Certainly, all these activity might
contribute to the adjuvant action on
ACT (Fig.1). However, direct effect on
CCL2 unmasking seems to be an absolute
requirement since ccr2
2/2 T lymphocytes
are still kept at the periphery of the
tumor whereas a significant recruitment
of TILs was achieved when native,
unmodified CCL2 was inoculated directly
within untreated tumors. Despite the
plethora of chemokine receptors able to
direct T lymphocytes, CCR2 is thus
essential to allow the completion of
trafficking process within the tumor mass,
suggesting the existence of an unexpected
territorial diversity within different tumor
districts.
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